國家藥監局:將持續完善疫苗管理體制 加快新藥好藥上市
國家藥監局披露,全國藥品監督管理工作會議於昨日(5日)召開,強調今年要堅守藥品安全底線。服務保障新階段疫情防控工作,加強防疫藥械質量監管,支持防疫重點藥械保產保供,持續做好應急審評審批工作;以長效化機制推進藥品安全專項整治常態化開展,有效打擊違法犯罪行為;持續完善疫苗管理體制,保障疫苗質量和供應;強化重點品種質量安全監管,堅持對產品質量問題「零容忍」,持續加強網絡銷售監管;全面加強風險隱患排查化解,統籌運用各類手段強化安全監管,完善藥物警戒和應急管理體系。
此外,要改革創新,促進醫藥產業高質量發展。推動營造雨林型醫藥創新生態,加快新藥好藥上市,促進高端創新醫療器械研發上市,釋放化妝品審評審批改革紅利,激發區域醫藥創新活力;促進中藥傳承創新發展,健全中藥監管制度體系,完善中藥審評審批機制,加強傳統藥國際交流合作;持續釋放「放管服」改革紅利,完善「互聯網+」政務服務,拓展涉企電子證照推廣應用,進一步優化營商環境。
還要全面提升藥品監管能力。健全完善藥品監管質量管理體系、法規制度體系、標準體系和科技支撐體系,加強技術支撐能力建設,大力發展智慧監管和監管科學,推進更高水平開放和更高質量國際合作,加快推進藥品監管體系和監管能力現代化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.